ReviewFrontiers in immunology2026
Taming autoimmune thyroiditis: cellular immunomodulation through MSCs, Tregs, and tolDCs.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Autoimmune thyroiditis and comorbid autoimmune diseases: global research landscape and future directions.Frontiers in immunology · 2026Pooled it
- Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune thyroiditis (AIT), typified by Hashimoto's thyroiditis, represents a prototypical organ-specific autoimmune disorder marked by lymphocytic infiltration, autoantibody production, and progressive thyroid dysfunction. Conventional hormone replacement alleviates hypothyroidism but fails to correct the underlying immune dysregulation. Preclinical models of experimental autoimmune thyroiditis (EAT) consistently demonstrate that these cell-based approaches mitigate inflammatory responses, correct Th17/Treg imbalance, and prevent follicular destruction. Moreover, emerging data on extracellular vesicle-mediated mechanisms and antigen-specific dendritic targeting further underscore the potential for durable immunological reprogramming. This review summarizes recent advances in tolerogenic cellular therapies aimed at restoring immune homeostasis in AIT. Mesenchymal stem cells (MSCs), regulatory T cells (Tregs), and tolerogenic dendritic cells (tolDCs) exert multifaceted immunomodulatory effects via cytokine secretion, metabolic reprogramming, and induction of antigen-specific tolerance, offering a promising immunotherapeutic strategy to modify AIT progression, moving beyond symptomatic relief toward long-term immune tolerance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.